- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 236395-14-5] Eslicarbazepine acetate
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-B0703 |
| Brand: | MCE |
| CAS: | 236395-14-5 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 296.32 |
| Molecular Formula | C17H16N2O3 |
| SMILES | O=C(N1C2=CC=CC=C2C[C@H](OC(C)=O)C3=CC=CC=C31)N |
Summary
Eslicarbazepine acetate (BIA 2-093), an antiepileptic drug, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel .
In Vivo
Eslicarbazepine acetate is an antiepileptic drug. It is a prodrug which is activated to eslicarbazepine (S-licarbazepine), an active metabolite of oxcarbazepine. Eslicarbazepine acetate is a prodrug for (S)-(+)-licarbazepine, the major active metabolite of oxcarbazepine. Its mechanism of action is therefore identical to that of oxcarbazepine. Eslicarbazepine acetate may not produce as high peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine which could theoretically improve tolerability [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02170649 | Bial - Portela C S.A. |
Epilepsy
|
September 2001 | Phase 1 |
| NCT02284854 | Bial - Portela C S.A. |
Epilepsy
|
July 2009 | Phase 1 |
| NCT02777671 | Bial - Portela C S.A. |
Epilepsy
|
October 2007 | Phase 1 |
| NCT02281448 | Bial - Portela C S.A. |
Epilepsy
|
March 2005 | Phase 1 |
| NCT01678976 | Bial - Portela C S.A. |
Epilepsy
|
March 2002 | Phase 1 |
| NCT02171195 | Bial - Portela C S.A. |
Epilepsy
|
July 2000 | Phase 1 |
| NCT02281591 | Bial - Portela C S.A. |
Epilepsy
|
June 2006 | Phase 1 |
| NCT02283814 | Bial - Portela C S.A. |
Epilepsy
|
January 2007 | Phase 1 |
| NCT00988429 | Bial - Portela C S.A.|Sunovion |
Partial Epilepsy
|
December 2, 2008 | Phase 3 |
| NCT00957684 | Bial - Portela C S.A. |
Refractory Partial Epilepsy
|
July 2004 | Phase 3 |
| NCT02283801 | Bial - Portela C S.A. |
Epilepsy
|
November 2006 | Phase 1 |
| NCT00971295 | Bial - Portela C S.A. |
Neuropathic Pain
|
October 2007 | Phase 1 |
| NCT02288312 | Bial - Portela C S.A. |
Epilepsy
|
May 2007 | Phase 1 |
| NCT01129960 | Bial - Portela C S.A. |
Painful Diabetic Neuropathy
|
November 2010 | Phase 3 |
| NCT01587339 | GlaxoSmithKline |
Epilepsy
|
September 2010 | |
| NCT02287415 | Bial - Portela C S.A. |
Epilepsy
|
May 2002 | Phase 1 |
| NCT02172755 | Bial - Portela C S.A. |
Epilepsy
|
June 2002 | Phase 1 |
| NCT00900237 | Bial - Portela C S.A. |
Partial Epilepsy
|
November 2008 | Phase 1 |
| NCT01879345 | Bial - Portela C S.A. |
Epilepsy
|
October 2004 | Phase 1 |
| NCT02283840 | Bial - Portela C S.A. |
Epilepsy
|
May 2007 | Phase 1 |
| NCT01879332 | Bial - Portela C S.A. |
Epilepsy
|
December 2006 | Phase 1 |
| NCT03116321 | Bial - Portela C S.A. |
Epilepsy
|
December 3, 2016 | Phase 1 |
| NCT02283788 | Bial - Portela C S.A. |
Epilepsy
|
March 2007 | Phase 1 |
| NCT02283827 | Bial - Portela C S.A. |
Epilepsy
|
January 2007 | Phase 1 |
| NCT02284828 | Bial - Portela C S.A. |
Epilepsy
|
September 2007 | Phase 1 |
| NCT00866775 | Sunovion |
Epilepsy With Simple or Complex Partial Onset Seizures
|
April 2009 | Phase 3 |
| NCT02281526 | Bial - Portela C S.A. |
Epilepsy
|
May 2005 | Phase 1 |
| NCT00957372 | Bial - Portela C S.A. |
Partial Epilepsy
|
December 2004 | Phase 3 |
| NCT00981227 | Bial - Portela C S.A. |
Postherpetic Neuralgia
|
November 2007 | Phase 2 |
| NCT02172742 | Bial - Portela C S.A. |
Epilepsy
|
May 2002 | Phase 1 |
| NCT01091662 | Sunovion |
Epilepsy
|
June 2010 | Phase 3 |
| NCT01824602 | Bial - Portela C S.A. |
BIPOLAR I DISORDER
|
February 2006 | Phase 2 |
| NCT01162460 | Bial - Portela C S.A. |
Epilepsy
|
December 2010 | Phase 3 |
| NCT01527513 | Bial - Portela C S.A. |
Partial Epilepsy
|
August 2010 | Phase 2 |
| NCT02279667 | Bial - Portela C S.A. |
Epilepsy
|
February 2004 | Phase 1 |
| NCT01825837 | Bial - Portela C S.A. |
Bipolar I Disorder
|
March 2006 | Phase 2 |
| NCT00988156 | Bial - Portela C S.A. |
Partial Epilepsy in Children and Adolescents
|
December 7, 2007 | Phase 3 |
| NCT01878578 | Bial - Portela C S.A. |
Epilepsy
|
November 2002 | Phase 1 |
| NCT00980746 | Bial - Portela C S.A. |
Painful Diabetic Neuropathy
|
November 2007 | Phase 2 |
| NCT01124097 | Bial - Portela C S.A. |
Post Herpetic Neuralgia
|
September 2010 | Phase 3 |
| NCT02284880 | Bial - Portela C S.A. |
Epilepsy
|
October 2010 | Phase 1 |
| NCT02171234 | Bial - Portela C S.A. |
Epilepsy
|
February 2001 | Phase 1 |
| NCT02281422 | Bial - Portela C S.A. |
Epilepsy
|
March 2005 | Phase 1 |
| NCT02170077 | Bial - Portela C S.A. |
Epilepsy
|
April 2002 | Phase 2 |
| NCT01830400 | Eisai Inc. |
Partial Onset Seizures
|
April 2012 | |
| NCT00957047 | Bial - Portela C S.A. |
Partial Epilepsy
|
July 2004 | Phase 3 |
| NCT01822678 | Bial - Portela C S.A. |
Bipolar I Disorder
|
December 2005 | Phase 2 |
| NCT00910247 | Sunovion |
Epilepsy
|
August 2009 | Phase 3 |
| NCT02912364 | Stanford University|Sunovion |
Epilepsy
|
July 2016 | Phase 4 |
| NCT02170064 | Bial - Portela C S.A. |
Epilepsy
|
June 2005 | Phase 2 |
| NCT03108729 | Sunovion |
Epilepsy
|
July 6, 2017 | Phase 3 |
| NCT01422720 | Bial - Portela C S.A. |
Epilepsy
|
April 2010 | Phase 3 |
| NCT01679002 | Bial - Portela C S.A. |
Epilepsy
|
October 2003 | Phase 1 |
| NCT03116828 | Sunovion |
Epilepsy With Partial On-set Seizures
|
July 7, 2017 | Phase 4 |
| NCT00987558 | Bial - Portela C S.A. |
Epilepsy
|
June 2009 | Phase 1 |
| NCT00898560 | Bial - Portela C S.A. |
Partial Epilepsy
|
September 2008 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 337.47 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.3747 mL | 16.8736 mL | 33.7473 mL |
| 5 mM | 0.6749 mL | 3.3747 mL | 6.7495 mL |
| 10 mM | 0.3375 mL | 1.6874 mL | 3.3747 mL |
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.